Investigating how entinostat and neoantigen vaccination can improve treatment for bladder cancer
Effects of entinostat and neoantigen vaccination on bladder cancer
This study is looking at a new way to help people with advanced bladder cancer by combining a special treatment called entinostat with a vaccine that targets cancer, to see if it can boost the immune system's ability to fight the disease, especially for those who haven't had success with other therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10913372 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for patients with advanced bladder cancer by exploring the effects of entinostat, a histone deacetylase inhibitor, combined with neoantigen vaccination. The study aims to understand how this combination can enhance the immune response against bladder cancer, particularly in patients who do not respond well to existing immune checkpoint blockade therapies. By examining the mechanisms behind these treatments in a mouse model, researchers hope to identify which patients are most likely to benefit and how to optimize their responses. The ultimate goal is to develop a more effective treatment strategy for bladder cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced bladder cancer who have not responded adequately to current immune checkpoint therapies.
Not a fit: Patients with early-stage bladder cancer or those who have not been diagnosed with bladder cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better survival rates for patients with advanced bladder cancer.
How similar studies have performed: Previous research has shown promising results with similar approaches in enhancing immune responses in cancer treatment, indicating potential for success in this study.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Beckabir, Wolfgang — Univ of North Carolina Chapel Hill
- Study coordinator: Beckabir, Wolfgang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.